These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 2005692)

  • 21. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.
    Splinter TA; Scher HI; Denis L; Bukowski R; Simon S; Klimberg I; Soloway M; Vogelzang NJ; van Tinteren H; Herr H
    J Urol; 1992 Mar; 147(3):606-8. PubMed ID: 1538438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
    González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
    Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
    Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
    J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CMV front-line chemotherapy in transitional bladder carcinoma.
    Paz-Ares L; Lianes P; Díaz-Puente M; Rivera F; Passas J; Costas P; Mendiola C; Cortés-Funes H
    Ann Oncol; 1993 Feb; 4(2):147-50. PubMed ID: 8448083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study.
    Fellin G; Graffer U; Bolner A; Ambrosini G; Caffo O; Luciani L
    Br J Urol; 1997 Jul; 80(1):44-9. PubMed ID: 9240179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
    Hoch V; Noll F; Schreiter F
    Urologe A; 1992 Jul; 31(4):243-6. PubMed ID: 1514212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term followup.
    Dreicer R; Kollmorgen TA; Smith RF; Williams RD
    J Urol; 1993 Sep; 150(3):849-52. PubMed ID: 8345598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of chemotherapy alternating with twice-a-day accelerated radiation therapy as an alternative to cystectomy in muscle infiltrating (stages T2 and T3) cancer of the bladder: preliminary results.
    Vikram B; Malamud S; Silverman P; Hecht H; Grabstald H
    J Urol; 1994 Mar; 151(3):602-4. PubMed ID: 8308967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
    Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group study.
    Meyers FJ; Palmer JM; Freiha FS; Harker EG; Shortliffe LD; Hannigan J; McWhirter K; Torti FM
    J Urol; 1985 Dec; 134(6):1118-21. PubMed ID: 3903223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Polychemotherapy in advanced bladder cancer. Practicality and clinical results].
    Klän R; Knispel H; Huland H
    Urologe A; 1992 Jul; 31(4):247-50. PubMed ID: 1514213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemotherapy (MVAC) in locally invasive bladder cancer.
    Sagaster P; Flamm J; Flamm M; Mayer A; Donner G; Oberleitner S; Havelec L; Lepsinger L; Ludwig H
    Eur J Cancer; 1996 Jul; 32A(8):1320-4. PubMed ID: 8869093
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
    Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Locally advanced or metastatic bladder carcinoma. Current aspects of therapy].
    Rübben H; Otto T
    Urologe A; 2001 Nov; 40(6):464-7. PubMed ID: 11760352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Neoadjuvant systemic chemotherapy with VMC (vinblastine, methotrexate and cisplatin) in locally advanced carcinoma of the bladder].
    Maffezzini M; Rigatti P
    Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):219-21. PubMed ID: 2142804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive bladder carcinoma: preliminary report of selective bladder conservation by transurethral surgery, upfront MCV (methotrexate, cisplatin, and vinblastine) chemotherapy and pelvic irradiation plus cisplatin.
    Marks LB; Kaufman SD; Prout GR; Heney NM; Griffin PP; Shipley WU
    Int J Radiat Oncol Biol Phys; 1988 Oct; 15(4):877-83. PubMed ID: 3182328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy.
    Soloway MS; Lopez AE; Patel J; Lu Y
    Cancer; 1994 Apr; 73(7):1926-31. PubMed ID: 8137219
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemotherapy for non-organ confined disease after radical cystectomy.
    Tekin A; Ozen H
    Int Urol Nephrol; 2000; 32(1):59-62. PubMed ID: 11057774
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.
    Scher HI; Yagoda A; Herr HW; Sternberg CN; Bosl G; Morse MJ; Sogani PC; Watson RC; Dershaw DD; Reuter V
    J Urol; 1988 Mar; 139(3):470-4. PubMed ID: 3343728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.